NDAORAL-28TABLET
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ESTROSTEP FE (ethinyl estradiol; norethindrone acetate) by Dr. Reddy's Laboratories. Approved for pregnancy. First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESTROSTEP FE is an oral contraceptive combining ethinyl estradiol (estrogen) and norethindrone acetate (progestin) in a 28-day tablet regimen. It is indicated for pregnancy prevention in women of reproductive age. The combination works by suppressing ovulation and altering cervical mucus to prevent conception.
LOE Approaching
This product faces significant competitive pressure (30 intensity score) and approaching loss of exclusivity, suggesting defensive strategy focus and likely contraction of brand team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
ESTROSTEP FE offers minimal career momentum due to zero linked job postings and approaching loss of exclusivity in a crowded market. Positions supporting this product tend to be defensive, focused on market retention rather than growth, and represent smaller team assignments compared to growth-stage franchises.
Brand Manager
Worked on ESTROSTEP FE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.